Nippon Shinyaku. 

$31.40
13
+$6.44+25.78% Friday 13:30

Statistics

Day High
31.4
Day Low
31.4
52W High
38.01
52W Low
21
Volume
-
Avg. Volume
-
Mkt Cap
0
P/E Ratio
10.92
Dividend Yield
1.23%
Dividend
0.39

Upcoming

Dividends

1.23%Dividend Yield
Jun 26
$0.39
Dec 25
$0.42
Jun 25
$0.41
Dec 24
$0.43
Jun 24
$0.41
10Y Growth
9.92%
5Y Growth
-3.07%
3Y Growth
-2.65%
1Y Growth
-6.6%

Earnings

11AugExpected
Q4 2024
Q1 2025
Q2 2025
Q3 2025
Q4 2025
Q1 2026
Next
0.22
0.53
0.84
1.15
Expected EPS
0.7767564
Actual EPS
N/A

Financials

20.11%Profit Margin
Profitable
2020
2021
2022
2023
2024
2025
1.35BRevenue
271.29MNet Income

People Also Follow

This list is based on the watchlists of people on Stock Events who follow NPNKF. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.

About

Nippon Shinyaku Co., Ltd., founded in Kyoto, Japan, in 1911, operates globally as a developer, manufacturer, and distributor of pharmaceutical products and functional foods. The company is organized into two primary divisions: Pharmaceuticals and Functional Food. Within its Pharmaceutical division, Nippon Shinyaku offers an extensive range of medications to markets across Japan, Switzerland, and other international territories. These therapeutic solutions address diverse medical challenges such as urological disorders, inflammatory and allergic conditions, hematologic malignancies, cardiovascular and metabolic diseases, and gastrointestinal ailments. Key pharmaceutical offerings include Zalutia and Eviprostat for benign prostatic urinary issues; Bladderon for frequent urination; Estracyt for prostate cancer; and Cialis for erectile dysfunction. Its oncology and hematology portfolio further encompasses Vidaza for myelodysplastic syndrome; Cylocide for solid tumors and acute leukemia; CylocideN for relapsed and refractory acute leukemia and malignant lymphoma; Gazyva, a humanized anti-CD20 monoclonal antibody; Defiterio for sinusoidal obstruction syndrome; and Trisenox and Amnolake for relapsed and refractory acute promyelocytic leukemia. The company also provides Uptravi, Adcirca, and Opsumit for pulmonary arterial hypertension; VILTEPSO for muscular dystrophy; Lunabel LD and Lunabel ULD for dysmenorrhea; Erizas, a dry powder inhaler for allergic rhinitis; Azunol Gargle liquid, an azulene-based gargling solution; Isobide for oral osmotic diuresis and Meniere's disease; Cephadol for vertigo; Livostin for allergic rhinitis and conjunctivitis; Regtect for maintaining alcohol abstinence; and Onetram and Tramal for the management of cancer and chronic pain. Beyond its existing product lines, Nippon Shinyaku actively invests in the research, development, and commercialization of new treatments within gynecology, otorhinolaryngology, and orthopedics. The Functional Food segment delivers a variety of health-oriented products, including health food ingredients, preservatives, protein preparations, supplements, and a selection of spices and condiments.
Show more...
CEO
Mr. Toru Nakai
Employees
2213
Country
Japan
ISIN
JP3717600005

Listings

0 Comments

Share your thoughts

FAQ

What is Nippon Shinyaku. stock price today?
The current price of NPNKF is $31.40 USD — it has increased by +25.78% in the past 24 hours. Watch Nippon Shinyaku. stock price performance more closely on the chart.
What is Nippon Shinyaku. stock ticker?
Depending on the exchange, the stock ticker may vary. For instance, on exchange Nippon Shinyaku. stocks are traded under the ticker NPNKF.
When is the next Nippon Shinyaku. earnings date?
Nippon Shinyaku. is going to release the next earnings report on August 11, 2026.
What were Nippon Shinyaku. earnings last quarter?
NPNKF earnings for the last quarter are 0.36 USD per share, whereas the estimation was 0.44 USD resulting in a -16.97% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Nippon Shinyaku. revenue for the last year?
Nippon Shinyaku. revenue for the last year amounts to 1.35B USD.
What is Nippon Shinyaku. net income for the last year?
NPNKF net income for the last year is 271.29M USD.
Does Nippon Shinyaku. pay dividends?
Yes, NPNKF dividends are paid semi-annual. The last dividend per share was 0.42 USD. As of today, Dividend Yield (FWD)% is 1.23%.
How many employees does Nippon Shinyaku. have?
As of June 11, 2026, the company has 2,213 employees.
In which sector is Nippon Shinyaku. located?
Nippon Shinyaku. operates in the Health & Wellness sector.
When did Nippon Shinyaku. complete a stock split?
Nippon Shinyaku. has not had any recent stock splits.
Where is Nippon Shinyaku. headquartered?
Nippon Shinyaku. is headquartered in Kyoto, Japan.